Nasdaq

Natera's Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

SAN CARLOS, Calif., Sept. 11, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Noridian, the Medicare Administrative ...
GEN

Looking Beyond NIPT, Natera Eyes Cancer, Transplant Testing Growth

Natera says it has begun making good on its priorities for 2021, which include expansions in noninvasive prenatal testing (NIPT), transplant rejection testing, minimal residual disease (MRD) cancer ...
Morningstar

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the validation study for its Latitude tissue-free ...
Nasdaq

Natera's Signatera™ Test Receives CE Mark

SAN CARLOS, Calif., Aug. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has received the CE mark for the Signatera ...

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether ...
Seeking Alpha

Natera: Poised For A Great Future But I'd Wait For A Pullback

Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. The company's competitive landscape is intense, with rivals ...
Yahoo Finance

Natera’s Signatera test to be used in Phase III bladder cancer trial

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
Seeking Alpha

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
Business Insider

Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq ...

SAN CARLOS, Calif. and SHENZHEN, China, March 11, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the ...
Zacks Investment Research on MSN

Natera files Signatera CDx PMA with FDA for bladder cancer MRD test

Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...
FiercePharma

Natera’s Non-Invasive Prenatal Testing Technology Shows Unparalleled Specificity, Sensitivity in Clinical Data Presented at American Society of Human Genetics

Natera presented additional data from an ongoing clinical study of the company’s non-invasive prenatal screening test that demonstrates consistently high detection of chromosomal abnormalities from ...